Please enable JavaScript to continue using this application.

Compare $RNA vs $SPRB | Chartloom

Compare

$RNA vs $SPRB

Atrium Therapeutics Inc · Spruce Biosciences, Inc

RNA

Atrium Therapeutics Inc

SPRB

Spruce Biosciences, Inc

Compare $RNA vs $SPRB

Comparing Atrium Therapeutics Inc and Spruce Biosciences, Inc

RNAAtrium Therapeutics Inc

SPRBSpruce Biosciences, Inc

RNAAtrium Therapeutics Inc

Market cap

$144M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

22.0%

YTD performance

-88.3%

52W performance

-82.6%

FCF yield

-55.5%

SPRBSpruce Biosciences, Inc

Market cap

$121M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-51.4%

52W performance

-72.5%

FCF yield

-35.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RNA

SPRB

Detailed metrics comparison

RNA

Atrium Therapeutics Inc

SPRB

Spruce Biosciences, Inc

Market Cap

RNA$144M

SPRB$121M

Enterprise Value

RNA$71M

SPRB$32M

Price

RNA$8.40

SPRB$44.05

P/E Ratio

RNAN/A

SPRBN/A

P/S Ratio

RNA3.48x

SPRB26.75x

EV/Sales

RNA1.73x

SPRB8.59x

EV/EBITDA

RNA0.00x

SPRB0.00x

P/B Ratio

RNA0.63x

SPRB1.57x

P/FCF Ratio

RNAN/A

SPRBN/A

EV/FCF

RNA-0.89x

SPRB-0.75x

PEG Ratio

RNAN/A

SPRBN/A

Forward P/E (NTM)

RNAN/A

SPRBN/A

Forward P/S (NTM)

RNAN/A

SPRBN/A

Revenue (TTM)

RNA$41M

SPRB$0

Revenue Growth (YoY)

RNA22.0%

SPRBN/A

Forward Rev Growth

RNA-94.2%

SPRB-75.6%

Gross Margin (TTM)

RNA0.0%

SPRB0.0%

Operating Margin (TTM)

RNA0.0%

SPRB0.0%

EBITDA Margin (TTM)

RNA-215.0%

SPRB0.0%

Net Margin (TTM)

RNA-209.2%

SPRB0.0%

FCF Margin (TTM)

RNA-193.4%

SPRBN/A

Net Income (TTM)

RNA$-86M

SPRB$-51M

FCF (TTM)

RNA$-80M

SPRB$-43M

EPS (TTM)

RNA-$5.05

SPRB-$21.14

ROE (TTM)

RNA-4030.0%

SPRB-15540.0%

ROA (TTM)

RNA-5864.0%

SPRB-10167.0%

ROIC (TTM)

RNA-4433.7%

SPRB-14349.0%

Cash

RNA$72M

SPRB$96M

Debt

RNA$0

SPRB$7M

Net Cash/Debt

RNA$72M

SPRB$89M

Current Ratio (TTM)

RNA8.73x

SPRB9.23x

Quick Ratio (TTM)

RNA8.59x

SPRB8.81x

Debt/Equity (TTM)

RNA0.00x

SPRB0.08x

Debt/Assets (TTM)

RNA0.0%

SPRB0.0%

Interest Coverage (TTM)

RNAN/A

SPRBN/A

Net Debt/EBITDA (TTM)

RNA0.00x

SPRB0.00x

Beta

RNA1.20

SPRB3.63

52W Performance

RNA-82.6%

SPRB-72.5%

YTD Performance

RNA-88.3%

SPRB-51.4%

% from 52W High

RNA-88.5%

SPRB-77.9%

% from 52W Low

RNA10.1%

SPRB9.2%

Asset Turnover (TTM)

RNA0.28x

SPRB0.07x

FCF Yield (TTM)

RNA-55.5%

SPRB-35.3%

Earnings Yield (TTM)

RNA-60.1%

SPRB-42.4%

Dividend Yield (TTM)

RNAN/A

SPRBN/A

Rule of 40

RNA-171.3

SPRB0.0

EV/GP/RG

RNAN/A

SPRBN/A

Ticker research

View RNA research View SPRB research

Metric	RNA Atrium Therapeutics Inc	SPRB Spruce Biosciences, Inc
Market & Valuation
Market Cap	$144M	$121M
Enterprise Value	$71M	$32M
Price	$8.40	$44.05
P/E Ratio	N/A	N/A
P/S Ratio	3.48x	26.75x
EV/Sales	1.73x	8.59x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.63x	1.57x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.89x	-0.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$41M	$0
Revenue Growth (YoY)	22.0%	N/A
Forward Rev Growth	-94.2%	-75.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-215.0%	0.0%
Net Margin (TTM)	-209.2%	0.0%
FCF Margin (TTM)	-193.4%	N/A
Net Income (TTM)	$-86M	$-51M
FCF (TTM)	$-80M	$-43M
EPS (TTM)	-$5.05	-$21.14
ROE (TTM)	-4030.0%	-15540.0%
ROA (TTM)	-5864.0%	-10167.0%
ROIC (TTM)	-4433.7%	-14349.0%
Financial Health
Cash	$72M	$96M
Debt	$0	$7M
Net Cash/Debt	$72M	$89M
Current Ratio (TTM)	8.73x	9.23x
Quick Ratio (TTM)	8.59x	8.81x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	3.63
52W Performance	-82.6%	-72.5%
YTD Performance	-88.3%	-51.4%
% from 52W High	-88.5%	-77.9%
% from 52W Low	10.1%	9.2%
Efficiency & Yields
Asset Turnover (TTM)	0.28x	0.07x
FCF Yield (TTM)	-55.5%	-35.3%
Earnings Yield (TTM)	-60.1%	-42.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-171.3	0.0
EV/GP/RG	N/A	N/A
Ticker research	View RNA research	View SPRB research

Valuation

P/S Ratio

RNA

3.48x

SPRB

26.75x

EV/FCF

RNA

-0.89x

SPRB

-0.75x

Growth & revenue

Revenue Growth TTM

RNA

22.0%

Forward Revenue Growth

SPRB

-75.6%

RNA

-94.2%

Profitability & performance

Gross Margin

RNA

0.0%

SPRB

0.0%

ROE

RNA

-4030.0%

SPRB

-15540.0%

FCF Yield %

SPRB

-35.3%

RNA

-55.5%

52-Week Performance

SPRB

-72.5%

RNA

-82.6%

Detailed metrics comparison

RNA

Atrium Therapeutics Inc

SPRB

Spruce Biosciences, Inc

Market Cap

RNA$144M

SPRB$121M

Enterprise Value

RNA$71M

SPRB$32M

Price

RNA$8.40

SPRB$44.05

P/E Ratio

RNAN/A

SPRBN/A

P/S Ratio

RNA3.48x

SPRB26.75x

EV/Sales

RNA1.73x

SPRB8.59x

EV/EBITDA

RNA0.00x

SPRB0.00x

P/B Ratio

RNA0.63x

SPRB1.57x

P/FCF Ratio

RNAN/A

SPRBN/A

EV/FCF

RNA-0.89x

SPRB-0.75x

PEG Ratio

RNAN/A

SPRBN/A

Forward P/E (NTM)

RNAN/A

SPRBN/A

Forward P/S (NTM)

RNAN/A

SPRBN/A

Revenue (TTM)

RNA$41M

SPRB$0

Revenue Growth (YoY)

RNA22.0%

SPRBN/A

Forward Rev Growth

RNA-94.2%

SPRB-75.6%

Gross Margin (TTM)

RNA0.0%

SPRB0.0%

Operating Margin (TTM)

RNA0.0%

SPRB0.0%

EBITDA Margin (TTM)

RNA-215.0%

SPRB0.0%

Net Margin (TTM)

RNA-209.2%

SPRB0.0%

FCF Margin (TTM)

RNA-193.4%

SPRBN/A

Net Income (TTM)

RNA$-86M

SPRB$-51M

FCF (TTM)

RNA$-80M

SPRB$-43M

EPS (TTM)

RNA-$5.05

SPRB-$21.14

ROE (TTM)

RNA-4030.0%

SPRB-15540.0%

ROA (TTM)

RNA-5864.0%

SPRB-10167.0%

ROIC (TTM)

RNA-4433.7%

SPRB-14349.0%

Cash

RNA$72M

SPRB$96M

Debt

RNA$0

SPRB$7M

Net Cash/Debt

RNA$72M

SPRB$89M

Current Ratio (TTM)

RNA8.73x

SPRB9.23x

Quick Ratio (TTM)

RNA8.59x

SPRB8.81x

Debt/Equity (TTM)

RNA0.00x

SPRB0.08x

Debt/Assets (TTM)

RNA0.0%

SPRB0.0%

Interest Coverage (TTM)

RNAN/A

SPRBN/A

Net Debt/EBITDA (TTM)

RNA0.00x

SPRB0.00x

Beta

RNA1.20

SPRB3.63

52W Performance

RNA-82.6%

SPRB-72.5%

YTD Performance

RNA-88.3%

SPRB-51.4%

% from 52W High

RNA-88.5%

SPRB-77.9%

% from 52W Low

RNA10.1%

SPRB9.2%

Asset Turnover (TTM)

RNA0.28x

SPRB0.07x

FCF Yield (TTM)

RNA-55.5%

SPRB-35.3%

Earnings Yield (TTM)

RNA-60.1%

SPRB-42.4%

Dividend Yield (TTM)

RNAN/A

SPRBN/A

Rule of 40

RNA-171.3

SPRB0.0

EV/GP/RG

RNAN/A

SPRBN/A

Ticker research

View RNA research View SPRB research

Metric	RNA Atrium Therapeutics Inc	SPRB Spruce Biosciences, Inc
Market & Valuation
Market Cap	$144M	$121M
Enterprise Value	$71M	$32M
Price	$8.40	$44.05
P/E Ratio	N/A	N/A
P/S Ratio	3.48x	26.75x
EV/Sales	1.73x	8.59x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.63x	1.57x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.89x	-0.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$41M	$0
Revenue Growth (YoY)	22.0%	N/A
Forward Rev Growth	-94.2%	-75.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-215.0%	0.0%
Net Margin (TTM)	-209.2%	0.0%
FCF Margin (TTM)	-193.4%	N/A
Net Income (TTM)	$-86M	$-51M
FCF (TTM)	$-80M	$-43M
EPS (TTM)	-$5.05	-$21.14
ROE (TTM)	-4030.0%	-15540.0%
ROA (TTM)	-5864.0%	-10167.0%
ROIC (TTM)	-4433.7%	-14349.0%
Financial Health
Cash	$72M	$96M
Debt	$0	$7M
Net Cash/Debt	$72M	$89M
Current Ratio (TTM)	8.73x	9.23x
Quick Ratio (TTM)	8.59x	8.81x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	3.63
52W Performance	-82.6%	-72.5%
YTD Performance	-88.3%	-51.4%
% from 52W High	-88.5%	-77.9%
% from 52W Low	10.1%	9.2%
Efficiency & Yields
Asset Turnover (TTM)	0.28x	0.07x
FCF Yield (TTM)	-55.5%	-35.3%
Earnings Yield (TTM)	-60.1%	-42.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-171.3	0.0
EV/GP/RG	N/A	N/A
Ticker research	View RNA research	View SPRB research